In the United States, a new monoclonal antibody (nirsevimab; trade name: Beyfortus) was recently approved by the FDA and recommended by the CDC to prevent Respiratory Syncytial Virus (RSV) in infants and toddlers. RSV poses a tremendous burden on patients and their families, and we look forward to seeing their suffering alleviated by implementation of this new immunization strategy.
EpidStrategies is proud to support this major public health endeavor through our many RSV studies (Publications | Epidstrategies). Please contact Mina Suh (msuh@epidstrategies.com) for more information about our RSV research program.